Active substances
Artemether + Lumefantrine
- US FDA 1
- UK MHRA 1
- NHS prices 1
- WHO EML 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| COARTEM | 20MG;120MG | tablet · oral | NOVARTIS | Prescription | 7 Apr 2009 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| RIAMET 20MG/120MG TABLETS | PL 23860/0024 | NOVARTIS IRELAND LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Artemether 20mg / Lumefantrine 120mg tablets | £22.50 | 24 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.5.3.1. Antimalarial medicines > Medicines for curative treatment · core
Malaria due to Plasmodium falciparum; Malaria due to Plasmodium vivax
Oral > Solid > dispersible tablet: 20 mg + 120 mg (EMLc) | Oral > Solid > tablet: 20 mg + 120 mg
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.